NeuroSense Therapeutics Stock Price, News & Analysis (NASDAQ:NRSN) $0.75 +0.03 (+3.61%) (As of 02:32 PM ET) Add Compare Share Share Today's Range$0.65▼$0.7650-Day Range$0.44▼$1.4952-Week Range$0.40▼$2.91Volume703,028 shsAverage Volume617,946 shsMarket Capitalization$8.22 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media About NeuroSense Therapeutics Stock (NASDAQ:NRSN)NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. Its lead product is PrimeC, an extended-release oral formulation of a fixed dose combination of ciprofloxacin and celecoxib for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.Read More NRSN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NRSN Stock News HeadlinesDecember 6, 2023 | finance.yahoo.comWe're A Little Worried About NeuroSense Therapeutics' (NASDAQ:NRSN) Cash Burn RateDecember 5, 2023 | marketwatch.comNeuroSense Therapeutics Sees Positive Safety Data in Phase 2 Trial for ALS Treatment, Shares FallDecember 7, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.December 5, 2023 | markets.businessinsider.comNeuroSense Says Phase 2b ALS Trial Meets Primary And Secondary EndpointsDecember 5, 2023 | msn.comNeuroSense ALS candidate meets key study goalsDecember 5, 2023 | finance.yahoo.comNeuroSense's Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy EndpointsDecember 4, 2023 | finance.yahoo.comNeuroSense to Report Phase 2b ALS Topline Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints on December 5, 2023November 28, 2023 | msn.comNeuroSense Therapeutics GAAP EPS of -$0.67December 7, 2023 | Edge On The Street (Ad)Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT?A little-known metal called vanadium is vital to American national security and energy independence. But right now, China and Russia dominate our supply. The U.S. Govt. is so serious about vanadium, it funded and recently completed an "Earth MRI" survey to seek out new sources of this energy metal - in Wyoming.November 28, 2023 | markets.businessinsider.comNeuroSense Therapeutics 9-Month Loss NarrowsNovember 28, 2023 | finance.yahoo.comNeuroSense Announces Third Quarter 2023 Financial Results and Provides Business UpdateNovember 13, 2023 | markets.businessinsider.comNeuroSense Therapeutics Concludes Successful Type D Meeting With FDA For ALS TreatmentNovember 13, 2023 | finance.yahoo.comNeuroSense Receives U.S. FDA Confirmation of CMC Strategy for PrimeC in Preparation for Pivotal Phase 3 in ALS and Commercial ReadinessNovember 6, 2023 | finance.yahoo.comNeuroSense Completes Dosing of Last Patient in the Double-Blind Segment of Phase 2b ALS Trial: Topline Clinical Efficacy Results Expected December 2023November 1, 2023 | finance.yahoo.comNeuroSense Therapeutics to Participate in BIO-Europe FallOctober 19, 2023 | finance.yahoo.comRenowned ALS Researcher Confirms The Efficacy Of NeuroSense Therapeutics’ Lead Drug Candidate, PrimeCOctober 17, 2023 | finance.yahoo.comNeuroSense CEO Provides Q3 2023 UpdateOctober 4, 2023 | finance.yahoo.comNeuroSense's PrimeC Demonstrates Outstanding Effect on ALS Survival in Innovative iPSC ModelSeptember 25, 2023 | barrons.comNeuroSense Therapeutics Ltd. WtSeptember 20, 2023 | finance.yahoo.comEuropean Medicines Agency Grants NeuroSense SME StatusSeptember 19, 2023 | finance.yahoo.comNeuroSense Granted Patents in Europe, Japan, and Israel for its ALS Drug PrimeCSeptember 14, 2023 | finance.yahoo.comNeuroSense to Participate in Upcoming ALS Conferences: PACTALS in Malaysia and NEALS in the U.S.September 6, 2023 | finance.yahoo.comNeuroSense to Host Investor Webinar on September 12, 2023August 16, 2023 | finance.yahoo.comNeuroSense Announces Second Quarter 2023 Financial Results and Provides Business UpdateJuly 17, 2023 | finance.yahoo.comNeuroSense to Host Investor Event in Cambridge, Massachusetts on July 24, 2023July 6, 2023 | finance.yahoo.comNeuroSense CEO Provides Q2 2023 UpdateJune 22, 2023 | finance.yahoo.comNeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private PlacementSee More Headlines Receive NRSN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NeuroSense Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today12/07/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/27/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NRSN CUSIPN/A CIK1875091 Webwww.neurosense-tx.com Phone972-9799-6183FaxN/AEmployees14Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.94) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-12,340,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-678.59% Return on Assets-174.61% Debt Debt-to-Equity Ratio0.04 Current Ratio1.82 Quick Ratio2.80 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.51 per share Price / Book1.42Miscellaneous Outstanding Shares10,940,000Free FloatN/AMarket Cap$7.93 million OptionableNot Optionable Beta1.65 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Alon Ben-Noon (Age 44)Co-Founder, CEO & Director Comp: $619kMr. Or Eisenberg (Age 42)Chief Financial Officer Comp: $378kDr. Ferenc Tracik M.D. (Age 59)Chief Medical Officer Comp: $513kMs. Hagit Binder (Age 45)Chief Operation Officer Dr. Niva Russek-Blum Ph.D. (Age 44)Chief Technology Officer Ms. Yael Barak (Age 53)VP of Quality & Compliance Ms. Keren PushettHead of HRMr. Eidan LoushiC.R.A.More ExecutivesKey CompetitorsProcessa PharmaceuticalsNASDAQ:PCSAJaguar HealthNASDAQ:JAGXAcer TherapeuticsNASDAQ:ACERQilian International Holding GroupNASDAQ:QLIAlaunos TherapeuticsNASDAQ:TCRTView All CompetitorsInstitutional OwnershipArmistice Capital LLCSold 604,000 shares on 11/15/2023Ownership: 6.051%View All Institutional Transactions NRSN Stock Analysis - Frequently Asked Questions Should I buy or sell NeuroSense Therapeutics stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NeuroSense Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NRSN shares. View NRSN analyst ratings or view top-rated stocks. How have NRSN shares performed in 2023? NeuroSense Therapeutics' stock was trading at $1.22 at the beginning of the year. Since then, NRSN stock has decreased by 42.2% and is now trading at $0.7046. View the best growth stocks for 2023 here. Are investors shorting NeuroSense Therapeutics? NeuroSense Therapeutics saw a increase in short interest in November. As of November 15th, there was short interest totaling 234,000 shares, an increase of 89.3% from the October 31st total of 123,600 shares. Based on an average daily volume of 240,800 shares, the days-to-cover ratio is currently 1.0 days. Approximately 2.6% of the company's stock are sold short. View NeuroSense Therapeutics' Short Interest. When is NeuroSense Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 27th 2024. View our NRSN earnings forecast. When did NeuroSense Therapeutics IPO? (NRSN) raised $13 million in an initial public offering (IPO) on Thursday, December 9th 2021. The company issued 2,000,000 shares at $6.00-$7.00 per share. Who are NeuroSense Therapeutics' major shareholders? NeuroSense Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Armistice Capital LLC (6.05%). How do I buy shares of NeuroSense Therapeutics? Shares of NRSN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:NRSN) was last updated on 12/7/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroSense Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.